These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 32726410

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Periostin and bone marrow fibrosis.
    Oku E, Kanaji T, Takata Y, Oshima K, Seki R, Morishige S, Imamura R, Ohtsubo K, Hashiguchi M, Osaki K, Yakushiji K, Yoshimoto K, Ogata H, Hamada H, Izuhara K, Sata M, Okamura T.
    Int J Hematol; 2008 Jul; 88(1):57-63. PubMed ID: 18465194
    [Abstract] [Full Text] [Related]

  • 45. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [Abstract] [Full Text] [Related]

  • 46. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
    Muth M, Engelhardt BM, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe HH, Bock O.
    Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [Recent advances in the treatment of myelofibrosis].
    Takenaka K.
    Rinsho Ketsueki; 2020 Jan; 61(9):1195-1204. PubMed ID: 33162516
    [Abstract] [Full Text] [Related]

  • 50. The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis.
    Uchiyama T, Kawabata H, Miura Y, Yoshioka S, Iwasa M, Yao H, Sakamoto S, Fujimoto M, Haga H, Kadowaki N, Maekawa T, Takaori-Kondo A.
    Cancer Med; 2015 Oct; 4(10):1558-72. PubMed ID: 26276681
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
    Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F.
    Oncotarget; 2017 Apr 25; 8(17):28187-28202. PubMed ID: 28390197
    [Abstract] [Full Text] [Related]

  • 54. Novel targets to cure primary myelofibrosis from studies on Gata1low mice.
    Zingariello M, Martelli F, Verachi P, Bardelli C, Gobbo F, Mazzarini M, Migliaccio AR.
    IUBMB Life; 2020 Jan 25; 72(1):131-141. PubMed ID: 31749302
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms.
    Li Y, Gao H, Dong H, Wang W, Xu Z, Wang G, Liu Y, Wang H, Ju W, Qiao J, Xu K, Fu C, Zeng L.
    Biochem Pharmacol; 2022 May 25; 199():115013. PubMed ID: 35318038
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis.
    Vermeersch G, Proost P, Struyf S, Gouwy M, Devos T.
    Haematologica; 2024 Jul 01; 109(7):2060-2072. PubMed ID: 38426279
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.